公开(公告)号：US20240335376A1

公开(公告)日：2024-10-10

申请号：US18749727

申请日：2024-06-21

申请人： AMNEAL COMPLEX PRODUCTS RESEARCH LLC

发明人： Kanji Meghpara ,  Jaydeep Vagashiya ,  Navnit H. Shah ,  Dipen Desai ,  Wantanee Phuapradit ,  Harpreet Kaur Sandhu ,  Siva Ram Kiran Vaka ,  Namdev B. Shelke ,  Ashish Chatterji

IPC分类号： A61K9/00 ,  A61K9/28 ,  A61K9/46 ,  A61K31/195 ,  A61K31/198 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/4412 ,  A61K31/4425 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

CPC分类号： A61K9/0065 ,  A61K9/0007 ,  A61K9/284 ,  A61K31/195 ,  A61K31/198 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/4412 ,  A61K31/4425 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

摘要： The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

公开(公告)号：US12076312B2

公开(公告)日：2024-09-03

申请号：US17692376

申请日：2022-03-11

申请人： Wisconsin Alumni Research Foundation

发明人： Gopal Iyer ,  Albert Wang

IPC分类号： A61K31/4166 ,  A61K31/167 ,  A61K31/277 ,  A61K31/4155 ,  A61K31/4439 ,  A61P37/06

CPC分类号： A61K31/4166 ,  A61K31/167 ,  A61K31/277 ,  A61K31/4155 ,  A61K31/4439 ,  A61P37/06

摘要： Use of an AR antagonist, e.g., enzalutamide and other known AR antagonists, for reducing inflammatory genes of COVID-19 subjects is provided by the present invention. In other aspects, the present invention is directed to the use of an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, to treat lung cancer in a subject. In yet other aspects, the present invention is directed to an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, as an immunotherapy.

公开(公告)号：US20240269149A1

公开(公告)日：2024-08-15

申请号：US18454012

申请日：2023-08-22

申请人： UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

发明人： Christopher M. ADAMS ,  Steven D. KUNKEL ,  Michael WELSH

IPC分类号： A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  G01N33/50

CPC分类号： A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  G01N33/5023 ,  C12Q2600/136 ,  G01N2800/10 ,  G01N2800/52

摘要： The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula:




or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f).

公开(公告)号：US12053454B2

公开(公告)日：2024-08-06

申请号：US16237442

申请日：2018-12-31

申请人： EVERGREEN BIOSCIENCES

发明人： Jason Dictenberg ,  Pavel Iserovich

IPC分类号： A61K31/4166 ,  A61K38/17 ,  A61K38/44 ,  A61K47/54 ,  A61P1/18 ,  A61P9/10 ,  A61P25/28

CPC分类号： A61K31/4166 ,  A61K38/1761 ,  A61K38/446 ,  A61K47/549 ,  A61P1/18 ,  A61P9/10 ,  A61P25/28 ,  C12Y115/01001

摘要： Provided herein are compositions for cryopreservation of mammalian cells, tissues, and organs. The compositions include a necroptosis inhibitor compound and a Bax channel inhibitor compound. Provided herein are also methods of use of the compositions, for treating, preventing, inhibiting, or reducing the incidence of cellular plasticity, or necroptosis or necrosis, of a plurality of cells, wherein the cells are brought into contact with the composition.

公开(公告)号：US20240165048A1

公开(公告)日：2024-05-23

申请号：US18526795

申请日：2023-12-01

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen Wright ,  Orrin Devinsky

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

CPC分类号： A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myocionic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US11963937B2

公开(公告)日：2024-04-23

申请号：US18320906

申请日：2023-05-19

申请人： GW Research Limited

发明人： Geoffrey Guy ,  Stephen Wright ,  Orrin Devinsky

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44

CPC分类号： A61K31/05 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/20 ,  A61K31/27 ,  A61K31/35 ,  A61K31/352 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/423 ,  A61K31/444 ,  A61K31/496 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/7048 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/44 ,  A61K31/352 ,  A61K2300/00 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/53 ,  A61K2300/00 ,  A61K31/5517 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/20 ,  A61K2300/00 ,  A61K31/423 ,  A61K2300/00 ,  A61K31/05 ,  A61K31/195 ,  A61K2300/00 ,  A61K2300/00

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US20240122846A1

公开(公告)日：2024-04-18

申请号：US18397458

申请日：2023-12-27

申请人： FTF PHARMA PRIVATE LIMITED

发明人： Nileshkumar Bhikhabhai PATEL ,  Lalchand Dataram GURJAR ,  Jayanta Kumar MANDAL

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

CPC分类号： A61K9/0053 ,  A61K9/08 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

摘要： The present invention relates to the oral pharmaceutical composition comprising an androgen receptor inhibitor and one or more pharmaceutically acceptable excipients selected from the group comprising of fillers/vehicles, solvents/co-solvents, preservatives/antioxidants, surfactants, buffering agents, chelating agents, sweetening agents, flavouring agents, sweetness/flavour enhancing agents, or combinations thereof. The present invention also relates to the processes for the preparation of the oral pharmaceutical composition comprising androgen receptor inhibitor and one or more pharmaceutically acceptable excipients.

公开(公告)号：US20240091218A1

公开(公告)日：2024-03-21

申请号：US18239304

申请日：2023-08-29

申请人： Corcept Therapeutics Incorporated

发明人： Grace Mann ,  Joseph Custodio ,  Iulia Cristina Tudor ,  Andrew Greenstein

IPC分类号： A61K31/4745 ,  A61K31/4166 ,  A61P35/00

CPC分类号： A61K31/4745 ,  A61K31/4166 ,  A61P35/00

摘要： Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator (SGRM) are disclosed. The AR antagonist may be enzalutamide. The SGRM may be an octahydro fused azadecalin compound, such as exicorilant, ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone which has the structure:




The AR antagonist and the SGRM may be administered once per day, and may be administered with food. Enzalutamide doses may be 150-200 mg/day, e.g., 160 mg/day. Exicorilant doses may be 100-350 mg/day, e.g., 240 mg/day, or 280 mg/day, or 320 mg/day.

公开(公告)号：US20240083883A1

公开(公告)日：2024-03-14

申请号：US18270624

申请日：2021-12-31

申请人： Sarissa Inc.

发明人： Mark David VINCENT ,  Peter John Ferguson ,  Donald James Koropatnick

IPC分类号： C07D403/14 ,  A61K31/138 ,  A61K31/4166 ,  A61K31/44 ,  A61K31/506 ,  A61K31/517 ,  A61P35/00 ,  C07D209/44 ,  C07D401/10 ,  C07D471/04

CPC分类号： C07D403/14 ,  A61K31/138 ,  A61K31/4166 ,  A61K31/44 ,  A61K31/506 ,  A61K31/517 ,  A61P35/00 ,  C07D209/44 ,  C07D401/10 ,  C07D471/04

摘要： The present invention provides RAD51 inhibitors having the structural formula (I): or a pharmaceutically acceptable salt or solvate thereof. Also provided are methods of treating or preventing cancer comprising administration of the compounds of the present invention, as well as uses of the compounds to induce a synergistic effect with known chemotherapeutic.

公开(公告)号：US20240009172A1

公开(公告)日：2024-01-11

申请号：US18218930

申请日：2023-07-06

申请人： The Regents of the University of Michigan ,  Oregon Health & Science University

发明人： Joshi Alumkal ,  Zheng Xia

IPC分类号： A61K31/4166 ,  A61P35/00 ,  C12Q1/6869 ,  C12Q1/6886

CPC分类号： A61K31/4166 ,  A61P35/00 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/106

摘要： The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for characterizing and treating prostate cancer (e.g., castration-resistant prostate cancer).